PWRM, CLNO, NHPR, MBA, GV, DEJ, - CRWEPicks.com Stock News! Power3 Medical Products, Cleantech Transit, National Health Partners, CIBT Education Group, Goldfield and Dejour Enterprises
Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical uses its Proteomic-based platform to analyze breast cancer at the protein level.
To date, they have identified over 120 distinct biomarkers relating to breast cancer.
In collaboration with a major research institute in Houston Texas, the Company has developed the Early Detection Breast Cancer Test, BC-SeraPro.
This test indicates, years prior to mammography, whether the patient has an early indication for breast cancer and if they require more testing or treatment.
Power3 believes the BC-SeraPro Test™ will become the standard precursor to the mammogram.
- In 2003, the breast cancer diagnostic market totaled $7 billion, which included $4.2 billion in mammograms and most of the remaining $2.8 billion in biopsy procedures.
- The global mammogram market is estimated at approximately $10 billion by the World Health Organization(WHO) and is growing especially in Asia where the incidences of breast cancer occur more frequently and at a younger age.
- Breast cancer is the second leading cause of cancer deaths in women today.
As a New technology for early detection, minimally-invasive BC-SeraPro™ Test from Power3 should participate favorably in the aforementioned mammogram market and has the potential to capture a significant portion of the pre-mammography early detection market. ( Read More http://crwepicks.com/?p=14938 )
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.